Baxter International Announces BAX 499 Study Results at ISTH

Baxter International reports new data from a series of studies during the 23rd annual congress of the ISTH in Kyoto.

Baxter International, a global and diversified healthcare company, has announced the pre-clinical data of BAX 499 for subcutaneous haemophilia therapy and final Phase I data on recombinant von Willebrand factor during the 23rd annual congress of the International Society on Thrombosis and Haemostasis (ISTH) in Kyoto, Japan.

The drug candidate, formerly known as ARC19499, is being studied in a Phase I clinical trial for subcutaneous administration to reduce the activity of the tissue factor pathway inhibitor, which plays a critical role in the blood coagulation cascade.

The 32-patient Phase I study evaluated the safety, tolerability, and pharmacokinetic profile of recombinant von Willebrand factor versus plasma-derived von Willebrand factor.